Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Jiale Song
Jefferies LLC, Research Division

All right. Welcome, everyone, to Jefferies Healthcare London Conference. My name is Roger Song, one of the senior analysts who cover semi-cap biotech in the U.S. It is my pleasure to introduce our presenting company, Viking Therapeutics, CEO, Brian Lian.

Brian Lian
President, CEO & Director

Thanks, Roger. Thanks to Jefferies for the invitation to present. I really have a great schedule today. So I really appreciate it. I’ll make some forward-looking statements today. I’d encourage anybody hearing this presentation to refer to the Securities and Exchange Commission website for the most current information on Viking Therapeutics.

I’m the Founder and CEO. We’re a San Diego-based company. We’ve got about 55 employees. We are focused on metabolic and endocrine disorders. We think our clinical programs have demonstrated best-in-class efficacy data. And we’ll talk a lot today about our metabolic disease program. So VK2735 is a GLP-1/GIP dual agonist that we’re developing for obesity. It’s currently in a Phase III program we call the VANQUISH program. We have an oral formulation of the same molecule that recently completed the Phase II study, and I’ll walk through some of those data today as well.

And then we have an amylin agonist that is approaching the clinic, and we expect to file an IND in the first quarter. We have additional programs focused on the thyroid receptor beta, 2 agonists: one, VK2809 that’s been through a Phase IIb study in MASH; and one, VK0214 that’s been through a Phase Ib study in X-linked adrenoleukodystrophy. We’re not actively developing those programs.

Here’s